Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials

Detalles Bibliográficos
Autores principales: Alecu, Iulian, Milenkova, Tsveta, Turner, Simon R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826089/
https://www.ncbi.nlm.nih.gov/pubmed/29505040
http://dx.doi.org/10.2147/DDDT.S156746
_version_ 1783302287858335744
author Alecu, Iulian
Milenkova, Tsveta
Turner, Simon R
author_facet Alecu, Iulian
Milenkova, Tsveta
Turner, Simon R
author_sort Alecu, Iulian
collection PubMed
description
format Online
Article
Text
id pubmed-5826089
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-58260892018-03-02 Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials Alecu, Iulian Milenkova, Tsveta Turner, Simon R Drug Des Devel Ther Letter Dove Medical Press 2018-02-21 /pmc/articles/PMC5826089/ /pubmed/29505040 http://dx.doi.org/10.2147/DDDT.S156746 Text en © 2018 Alecu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Letter
Alecu, Iulian
Milenkova, Tsveta
Turner, Simon R
Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials
title Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials
title_full Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials
title_fullStr Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials
title_full_unstemmed Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials
title_short Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials
title_sort risk of severe hematologic toxicities in cancer patients treated with parp inhibitors: results of monotherapy and combination therapy trials
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826089/
https://www.ncbi.nlm.nih.gov/pubmed/29505040
http://dx.doi.org/10.2147/DDDT.S156746
work_keys_str_mv AT alecuiulian riskofseverehematologictoxicitiesincancerpatientstreatedwithparpinhibitorsresultsofmonotherapyandcombinationtherapytrials
AT milenkovatsveta riskofseverehematologictoxicitiesincancerpatientstreatedwithparpinhibitorsresultsofmonotherapyandcombinationtherapytrials
AT turnersimonr riskofseverehematologictoxicitiesincancerpatientstreatedwithparpinhibitorsresultsofmonotherapyandcombinationtherapytrials

Ejemplares similares